おすすめの製品
由来生物
mouse
品質水準
100
500
結合体
unconjugated
抗体製品の状態
culture supernatant
抗体製品タイプ
primary antibodies
クローン
211F1.1, monoclonal
詳細
For In Vitro Diagnostic Use in Select Regions (See Chart)
形状
buffered aqueous solution
化学種の反応性
human
包装
vial of 0.1 mL concentrate (387M-14)
vial of 0.5 mL concentrate (387M-15)
bottle of 1.0 mL predilute (387M-17)
vial of 1.0 mL concentrate (387M-16)
bottle of 7.0 mL predilute (387M-18)
メーカー/製品名
Cell Marque™
テクニック
immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:25-1:100
アイソタイプ
IgG2aκ
コントロール
astrocytoma
輸送温度
wet ice
保管温度
2-8°C
視覚化
nuclear
遺伝子情報
human ... OLIG2(10215)
関連するカテゴリー
詳細
Olig2, a basic helix–loop–helix transcription factor, is involved in oligodendroglial specification. Olig2 expression has been reported in most glial tumors, such as oligodendrogliomas and astrocytomas. Although more than half of glioblastomas are positive for Olig2, expression is very weak in terms of both percentage of labeled cells and intensity. No Olig2 expression has been found in the non-glial tumors including neuroepithelial tumors, ependymomas, subependymomas, medulloblastomas, and nonneuroepithelial tumors, such as CNS lymphomas, meningiomas, schwannomas, atypical teratoid/rhabdoid tumor, and haemangioblastomas. Compared to the strong staining seen in glioma samples, a weak expression is observed in non-tumoral brain tissue (gliosis). In order to characterize cellular subtypes that constitute astrocytomas, oligoastrocytomas and oligodendrogliomas, double labeling of Olig2 and GFAP has been performed which identified two phenotypically distinct tumor populations. The first is Olig2+/GFAP– which has an oligodendroglial morphology, corresponding to pure oligodendrogliomas that contain only oligodendroglial cells; the second is Olig2–/GFAP+ which has an astrocytic phenotype, including not only oligoastrocytomas, but also WHO astrocytomas. Depending on proportion and spatial clustering of the two phenotypically distinct tumor populations, the tumor (Olig2-/GFAP+) is classified either as an astrocytoma when both populations are intermingled with a dominance of GFAP+ cells or oligoastrocytoma when there is some degree of spatial clustering of the GFAP+ cells.
品質
IVD | IVD | IVD | NA |
関連事項
Olig2 Positive Control Slides, Product No. 387S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).
物理的形状
Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide
調製ノート
Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.
その他情報
For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com
法的情報
Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany
適切な製品が見つかりませんか。
製品選択ツール.をお試しください
試験成績書(COA)
製品のロット番号・バッチ番号を入力して、試験成績書(COA) を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。
Neuropathology and applied neurobiology, 31(1), 62-69 (2005-01-07)
The expression of Olig2, a basic helix-loop-helix (bHLH) transcription factor involved in oligodendroglial specification, was investigated by immunohistochemistry in a series of 146 tumours and control samples. Olig2 expression was restricted to glial tumours and nontumoral oligodendrocytes. It was higher
Journal of neuro-oncology, 104(2), 423-438 (2011-01-05)
The bHLH transcription factor, OLIG2, is universally expressed in adult human gliomas and, as a major factor in the development of oligodendrocytes, is expressed at the highest levels in low-grade oligodendroglial tumors. In addition, it is functionally required for the
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら(テクニカルサービス)